DARZALEX (daratumumab) generated $3.24 billion in global net sales during Q1 2025, with $1.83 billion from U.S. markets and $1.41 billion internationally.
AbbVie has filed a lawsuit against Genmab and ProfoundBio alleging misappropriation of trade secrets related to disaccharide technology in antibody-drug conjugates, which Genmab categorically refutes.
AbbVie's final analysis of the phase III MIRASOL trial confirms Elahere (mirvetuximab soravtansine) provides superior efficacy compared to chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer patients.
Luveltamab tazevibulin demonstrated a 32% overall response rate in platinum-resistant ovarian cancer patients with FRα expression ≥25%, showing similar efficacy in both low-medium and high expression subgroups.
Johnson & Johnson has decided not to exercise its option to license Genmab's HexaBody-CD38 antibody therapeutic, despite promising clinical efficacy data in multiple myeloma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.